The industry is significantly focused on the implications of next April's 'catch-up' statutory price reductions but it might need to take a wider view of what are much broader and fundamental changes to the policy infrastructure of the PBS that will have an enduring impact.
Companies hit hard by the new price cut 'flow on' mechanism
August 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 12 December
December 12, 2025 - - Podcast -
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech
